Maze Therapeutics

MAZE

Market cap $1.88B

Maze Therapeutics, Inc. ( MAZE ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:00 AM EST Company Participants Jason Coloma - CEO & Director Presentation Jason Coloma CEO & Director Good morning, everyone. I'm Jason Coloma.

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the third quarter ended September 30, 2025, highlighting recent progress and business updates.

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentations at the American Society of Nephrology's (ASN) Kidney Week, being held November 6-9 in Houston, Texas.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November 11, 2025, at 9:30 a.m.

Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease.

CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D.

Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.

Maze Therapeutics, Inc. (NASDAQ:MAZE ) MZE782 Phase 1 Healthy Volunteer Trial Results Conference September 11, 2025 08:30 AM ET Company Participants Amy Bachrodt Jason Coloma - CEO & Director Harold Bernstein - President of Research & Development and Chief Medical Officer Misbah Tahir - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Presentation Operator Good morning.

Maze Therapeutics, Inc. MAZE on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.